Date: 2014-10-15
Type of information: IPO
Company: Forward Pharma (Denmark)
Investors:
Amount: $235.2 million
Funding type: IPO
Planned used:
Others: * On November 14, 2014, Forward Pharma, a biopharmaceutical company working to advance a proprietary formulation of dimethyl fumarate for the treatment of multiple sclerosis and other immune disorders such as psoriasis, announced that it closed the sale of an additional 699,980 American Depositary Shares ("ADSs") at the initial public offering price of $21.00 per ADS, pursuant to the over-allotment option being exercised in part by the underwriters of its recently completed intial public offering. With this exercise, the Company's initial public offering amounts to a total of 11,199,980 ADSs, representing gross total proceeds of $235.2 million to the Company before deducting underwriting discounts and commissions and other offering fees and expenses. * On October 15, 2014, Forward Pharma announced the pricing of its initial public offering of 10,500,000 American Depositary Shares (ADS), representing the Company\'s ordinary shares, at a price to the public of $21.00 per ADS. The ADSs are expected to begin trading today on the NASDAQ Global Select Market under the ticker symbol \"FWP\". The Company has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 ADSs to cover over-allotments, if any. Leerink Partners LLC, Jefferies LLC and RBC Capital Markets, LLC are acting as joint book-running managers. JMP Securities LLC is acting as co-manager. * On August 11, 2014, Forward Pharma has filed a registration statement on Form F-1 with the United States Securities and Exchange Commission relating to a proposed initial public offering of its ordinary shares. The number of shares to be offered and the price range for the offering have not yet been determined.
The Company's ADSs began trading on the NASDAQ Global Select Market on October 15, 2014, under the ticker symbol "FWP."
Therapeutic area: Autoimmune diseases - Neurodegenerative diseases
